Le Lézard
Classified in: Health
Subjects: PDT, SBS

HERO® Releases California Compliant Self-Defense Tools


SALT LAKE CITY, Dec. 15, 2023 /PRNewswire/ -- HERO Defense Systems LLC has announced a new collection of California Compliant self-defense products. Available options include both the company's patented, non-lethal defense devices: HERO® 2020, and AIIRO®. The new bundles are designed and labeled to meet California state regulations for self-defense weapons, allowing residents to finally utilize these award-winning defense tools.

Introducing BluntForcetm Non-Lethal Self Defense

This newly announced cartridge, known as BluntForcetm, is available in multiple California compliant bundles of HERO 2020 and CORE devices. It comes pre-loaded with .68 caliber hard polymer projectiles and fires at over 150 mph. The cartridge deters and stops attackers with a targeted, painful punch of localized kinetic energy.

"California restricts pepper irritant projectiles, and customers have been asking us for years to provide them options. Now we have. BluntForce is a pre-built, no mess, ready to use defense tool, built at our factory in Utah. It's a reliable solution that instantly causes pain to an attacker."

-    David Clemons, CEO and Co-Founder, HERO Defense Systems

AIIRO® Gel Based Defense

AIIRO® bundles and cartridges can now be shipped to California residents as well, with multiple kit and color options available. The AIIRO® device fires sticky non-lethal irritant gel, causing intense burning sensations, temporary blindness, fits of coughing, and discomfort. There are no long-term effects and effects can last up to an hour.

Award-Winning Protection for Californians

HERO® has begun marking eligible products with a California Compliant icon and has created a section on their website listing all currently available bundles.

HERO® products are not considered firearms under federal law. Some restrictions on usage and age may apply in certain states.

To contact HERO® regarding quotes, interview, or speaking opportunities, contact:

HERO Defense Systems LLC
[email protected]
(833) 437-6669

For more information about HERO Defense Systems and products, visit www.HERO.US.com or join the non-lethal movement on social: @Bringahero

SOURCE HERO Defense Systems


These press releases may also interest you

at 02:27
Global Biometric Technologies Market Share, Trends, Size, Players, Statics, Facts, Opportunity & Forecast (2024-2031) | Pheonix Research
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:05
Locate Bio Raises £9.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody Fusion
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

at 02:05
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 01:00
Philips delivers first-quarter results in line with 2024 performance improvement plan; Resolves the Respironics personal injury and medical monitoring litigation in the US for USD 1.1 billion
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma Announces Total Capital of ?15 Million Successfully Secured in Second Closing
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...

More news about Health...


News published on and distributed by: